

Special Issue

Adjuvant Therapy in Cancer

Message from the Guest Editor

Carcinomas of the head and neck region are among the most common tumors and pose considerable challenges not only to the treating physician but also to patients and their relatives. Primary and adjuvant therapeutic approaches vary depending on the localization of the primary tumor, histology, patients' general condition and the wishes of the patient. Adjuvant therapy—an almost endless topic—begins with radiation and chemotherapy and ends with rehabilitation procedures such as speech and language, physiotherapy and occupational therapy, as well as dietary supplements. This Special Issue intends to provide an overview of current and, above all, state-of-the-art adjuvant therapy for head and neck cancer patients, and thus, open up new insights for physicians. With this letter, I cordially invite all colleagues from the fields of head and neck surgery, radiation therapy, plastic and reconstructive surgery, oncology, speech and language, occupational therapy, nutritional sciences, and rehabilitation to contribute their data and experiences to the readership of *Cancers*.

Guest Editor

Dr. Boban M. Erović

Institute of Head and Neck Diseases, Evangelical Hospital, 1180 Vienna, Austria

Deadline for manuscript submissions

closed (15 April 2023)



Cancers

an Open Access Journal
by MDPI

Impact Factor 4.4
CiteScore 8.8
Indexed in PubMed



mdpi.com/si/100663

Cancers
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
cancers@mdpi.com

[mdpi.com/journal/
cancers](https://mdpi.com/journal/cancers)





Cancers

an Open Access Journal
by MDPI

Impact Factor 4.4
CiteScore 8.8
Indexed in PubMed



[mdpi.com/journal/
cancers](https://mdpi.com/journal/cancers)



About the Journal

Message from the Editor-in-Chief

Cancers is an international online journal addressing both clinical and basic science issues related to cancer research. The journal is publishing in Open Access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

Editor-in-Chief

Prof. Dr. Samuel C. Mok

Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Oncology) / CiteScore - Q1 (Oncology)